ADTRALZA

Brand name authorized in: Ireland Lithuania Poland United Kingdom

Active ingredients

The drug ADTRALZA contains one active pharmaceutical ingredient (API):

1 Tralokinumab
UNII GK1LYB375A - TRALOKINUMAB

Tralokinumab is a fully human IgG4 monoclonal antibody that specifically binds to the type 2 cytokine interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptors. IL-13 is a major driver of human type 2 inflammatory disease, such as atopic dermatitis and inhibiting the IL-13 pathway with tralokinumab in patients decreases many of the mediators of type 2 inflammation.

Read about Tralokinumab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Tralokinumab
D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AH Agents for dermatitis, excluding corticosteroids
Discover more medicines within D11AH07

Medication package inserts

Below package inserts are available for further reading:

Title
Type
Country
Summary of Product Characteristics (SPC)

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
GB
Medicines & Healthcare Products Regulatory Agency
Identifier(s): 399359
LT
Valstybinė vaistų kontrolės tarnyba
Identifier(s): 1092843, 1092844, 1092845
PL
Rejestru Produktów Leczniczych
Identifier(s): 100455323